Richard Bernstein Advisors LLC Sells 19,373 Shares of CVS Health Corporation $CVS

Key Points

• Richard Bernstein Advisors cut its stake in CVS by 51.1% in Q3, selling 19,373 shares and leaving a 18,562‑share holding worth about $1.40 million.
• Wall Street sentiment is broadly positive with a consensus rating of “Moderate Buy” and a $94.91 average price target, as several firms have recently maintained or raised overweight/outperform ratings.
• CVS recently reported an earnings beat (EPS $1.09 vs. $1.00 expected) and revenue of $105.69B (up 8.2% YoY); the stock pays a $0.665 quarterly dividend (3.5% yield) though its payout ratio is elevated at 192.75%.

Richard Bernstein Advisors LLC cut its position in CVS Health Corporation (NYSE:CVS - Free Report) by 51.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,562 shares of the pharmacy operator's stock after selling 19,373 shares during the quarter. Richard Bernstein Advisors LLC's holdings in CVS Health were worth $1,399,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. SOA Wealth Advisors LLC. increased its holdings in shares of CVS Health by 36.9% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator's stock worth $37,000 after purchasing an additional 131 shares during the period. Alteri Wealth LLC lifted its position in shares of CVS Health by 3.2% during the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator's stock worth $316,000 after buying an additional 131 shares during the period. Holistic Financial Partners boosted its stake in shares of CVS Health by 4.1% in the 3rd quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator's stock valued at $256,000 after purchasing an additional 133 shares in the last quarter. Symmetry Partners LLC boosted its position in CVS Health by 2.5% in the third quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator's stock valued at $439,000 after buying an additional 141 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in shares of CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator's stock worth $26,000 after acquiring an additional 142 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CVS shares. Piper Sandler reissued an "overweight" rating and set a $101.00 price target (up from $99.00) on shares of CVS Health in a research note on Wednesday, December 10th. Morgan Stanley upped their price target on CVS Health from $89.00 to $93.00 and gave the company an "overweight" rating in a research note on Wednesday, December 10th. JPMorgan Chase & Co. boosted their target price on CVS Health from $93.00 to $101.00 and gave the company an "overweight" rating in a research note on Wednesday, December 17th. Wolfe Research dropped their price objective on shares of CVS Health from $100.00 to $97.00 and set an "outperform" rating on the stock in a report on Monday, March 2nd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of CVS Health in a research note on Wednesday, December 10th. Nineteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.91.

CVS Health Stock Down 2.7%

Shares of CVS stock opened at $76.15 on Wednesday. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $85.15. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. The stock has a market cap of $96.87 billion, a price-to-earnings ratio of 55.18, a PEG ratio of 0.82 and a beta of 0.49. The firm's 50-day moving average is $78.39 and its 200-day moving average is $77.73.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion for the quarter, compared to the consensus estimate of $103.67 billion. During the same quarter in the previous year, the business earned $1.19 earnings per share. The business's revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Sell-side analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a yield of 3.5%. CVS Health's dividend payout ratio (DPR) is currently 192.75%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.